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Fanconi anemia (FA) is an inherited DNA repair disorder associated with short stature and bone marrow
failure, usually requiring hematopoietic cell transplantation (HCT). Although low bone mineral density (BMD)
has been reported in leukemia patients after HCT, little is known about BMD in FA children after HCT (FA
HCT). This study’s goals were to compare BMD in FA HCT to BMD in healthy controls and in children who
received HCT for hematologic malignancy (cancer HCT), and to test for associations between BMD and risk
factors for bone loss. This cross-sectional study included 20 FA HCT, 13 cancer HCT, and 90 healthy controls,
age-matched and <18 years old at evaluation. BMD Z-scores for total body (TBMD) and lumbar spine (LBMD)
were measured by dual energy x-ray absorptiometry and adjusted for height-for-age Z-score (HAZ). FA HCT
had lower mean TBMDHAZ Z-score (by .8 SD) and higher fraction with Z-score  1 than healthy controls (42%
versus 11%). No LBMD deﬁcits were detected. FA HCT and cancer HCT groups did not differ signiﬁcantly
in TBMD or LBMD Z-scores. In FA HCT patients, lower body mass index and lower percent fat were associated
with lower BMD. This study highlights the importance of monitoring BMD to optimize bone health in
FA patients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Fanconi anemia (FA) is an inherited DNA repair disorder
associated with short stature, congenital anomalies,
including limb and vertebral defects, and a high risk for bone
marrow failure, leukemia, and other malignancy [1-4]. He-
matopoietic cell transplantation (HCT) is the only potential
curative therapy for these hematologic manifestations [5],
but it also carries a risk of long-term consequences.
Low bonemineral density (BMD) has been documented in
children and adults who received HCT for hematologic ma-
lignancies [6-9]. Risk factors include inadequate calcium or
vitamin D intake, total body irradiation (TBI), age at HCT, sex,edgments on page 898.
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ty for Blood and Marrow Transplantation.reduced lean body mass, graft-versus-host disease (GVHD),
and endocrinopathies, such as hypogonadism and growth
hormone deﬁciency. Although many of these risk factors are
prevalent in FA patients [3,4,10,11], bone health in the FA
population is poorly understood. Only 2 published studies
have addressed BMD in children with FA [9,12], both using
dual energy x-ray absorptiometry scan (DXA). However, it
remains unclear to what extent children with FA manifest
BMD deﬁcits after HCT, to what degree DXA results are
affected by short stature in this patient population, and
which skeletal sites are most informative.
This study’s primary goal was to evaluate BMD in FA
children after HCT. Secondary goals were to determine if
BMD of children with FA is affected to a similar degree as
BMD of children who received HCT for a malignancy, and to
test for an association between BMD and risk factors for bone
loss in patients with FA.We hypothesized that (1) mean BMD
Z-score is lower in FA HCT recipients than healthy controls;
A. Petryk et al. / Biol Blood Marrow Transplant 21 (2015) 894e899 895(2) FA HCT recipients have higher BMD Z-scores than cancer
HCT recipients, as they have not been heavily treated with
chemotherapy before the HCT preparative therapy; and (3)
hypogonadism and vitamin D deﬁciency are associated with
lower BMD Z-score in FA [13]. The current study addresses
the existing gaps by including a control group of healthy
subjects of a similar age, using both lumbar spine and total
body BMD measures, and by including FA patients who all
underwent transplantation with a uniform conditioning
regimen under the same protocol.
MATERIALS AND METHODS
Participants
All FA patients who underwent an alternative donor HCT using the same
regimen consisting of TBI 300 cGy, cyclophosphamide 40mg/kg, ﬂudarabine
140 mg/m2, and antithymocyte globulin 150 mg/kg, between 2006 and
2013, and who survived at least 1 year after HCT were identiﬁed using the
database of the University of Minnesota’s blood andmarrow transplantation
program. Forty patients were identiﬁed, ages 6.5 to 34.1 years.
Two comparison groups were selected for this cross-sectional study
from previously published cohorts: normal healthy controls [14] and pa-
tients who received HCT for hematologic malignancy [6]. The original group
of healthy controls included 208 siblings of cancer patients treated at the
University of Minnesota Masonic Children’s Hospital and Children’s Hospi-
tals and Clinics of Minnesota, ages 9 to 18 years at evaluation [14]. The
original group of patients who received HCT for hematologic malignancy
included 151 patients, ages 10 to 50.5 years at evaluation, who underwent
transplantation at the University of Minnesota or the Fred Hutchinson
Cancer Research Center/Seattle Children’s Hospital [6]. Because of signiﬁ-
cant age and, hence, Tanner stage differences between the groups (both of
which are important in BMD assessment), to be able to compare results
between the groups, the inclusion limits for age at evaluation (ie, DXA scan)
were progressively narrowed until the groups did not test signiﬁcantly
different for these 2 variables. The ﬁnal study population included 20 FA
children (FA HCT group), 90 normal healthy controls, and 13 children who
received HCT for hematologic malignancy (cancer HCT group). The study
was approved by the Institutional Review Boards at the University of Min-
nesota and the Fred Hutchinson Cancer Research Center/Seattle Children’s
Hospital.
Study Procedures
All patients underwent a physical examination, including Tanner staging
of pubertal development by trained pediatric providers, measurement of
height, weight, and body mass index (BMI), and a DXA scan (GE Healthcare
Lunar Prodigy scanner; Madison, WI) using enCORE software version 9.3 at
the University of Minnesota and version 8.1 at Seattle Children’s Hospital.
DXAmeasures included Z-scores for total body BMD (TBMD), including head,
and posterior anterior lumbar spine BMD (LBMD) at L1 to L4 for FA patients,
and at L2 to L4 for healthy controls and cancer patients, with and without
adjusting for height-for-age Z-score (HAZ) [15], as well as body composition
(percent fat mass, lean body mass). The 2 GE Healthcare Lunar Prodigy DXA
scanners were cross-calibrated using a custom-built phantom allowing cali-
bration of bone, fat, and lean tissue mass. Data from the 2 scanners were
corrected for differences between them. Sex- and age-speciﬁc BMD Z-scores
were calculated using enCORE reference data based on healthy, ambulatory
subjects from the general population who were free from chronic diseases
affecting bone and not taking bone-altering medications.
Laboratory testing included free thyroxine (free T4) by competitive
immunoassay and total testosterone by liquid chromatography/tandemmass
spectrometry. Chemiluminescent immunoassay was performed to measure
25-hydroxyvitamin D, estradiol, follicle-stimulating hormone, and luteinizing
hormone. Hypothyroidism was deﬁned by treatment with thyroid hormone
replacement at the time of examination or free T4 < .7 ng/dL (9 pmol/L).
Hypergonadotropic hypogonadism was deﬁned by follicle-stimulating hor-
mone >40 IU/L in females >10 years or luteinizing hormone >10 IU/L and
testosterone below normal for Tanner stage in males >11 years [16].
Statistical Analysis
Descriptive statistics are shown as frequencies and percentages, as
mean  standard deviation (SD) for unadjusted analyses, or as adjusted
average  standard error (SE) for adjusted analyses. For unadjusted com-
parisons between FA HCT and cancer HCT patients, P values are from a 2-
sample t-test or Fisher’s exact test. Otherwise, all analyses had the form of
multivariate linear or logistic regression, depending on the outcome, and all
used generalized estimating equations with robust standard errors to account
for sibling relationships within the healthy control group. Analyses testing theassociation between BMD Z-score and risk factors in FA patients were
adjusted for Tanner stage. Analyses comparing BMD Z-score between groups
were adjusted for age at study, gender, and Tanner stage. Height-adjusted
BMD Z-scores were calculated using a method described by Zemel et al.
[15]. All analyses were done using the SAS system (v. 9.3; SAS Institute, Cary,
NC). P values are 2-sided and <.05 is considered statistically signiﬁcant,
except for analyses involving multiple comparisons, in which P value < .0167
is considered statistically signiﬁcant using a Bonferroni adjustment.
RESULTS
Characteristics of the Study Groups
Table 1 shows participant characteristics. By design, age
and Tanner stage at DXA evaluation did not differ between the
groups; all patients were 10 to 14 years old. At time of HCT, 19
FA patients had aplastic anemia and 1 patient had myelo-
dysplastic syndrome. Complementation groups included
FANCA (n ¼ 13), FANCC (n ¼ 4), FANCE (n ¼ 1), FANCG (n ¼ 1),
and unknown (n ¼ 1). The cancer HCT group had a higher
percentage of males compared with healthy controls; 6 had
acute myeloid leukemia, 4 had acute lymphoblastic leukemia,
1 had chronic myelogenous leukemia, 1 had myelodysplastic
syndrome, and 1 had non-Hodgkin lymphoma. Compared
with the FA HCT group, the cancer HCT group was younger at
HCTand had DXA scans later after HCT. Themedian time since
HCT was 2.2 years for FA patients and 5.2 years for cancer
patients. Only 1 FA patient received androgen treatment
before HCT. Two FA patients had grade IIeIV acute GVHD
requiring systemic steroid therapy, 1 of whom also had
chronic GVHD. The incidence of acute, but not chronic, GVHD
was higher in cancer patients than in FA patients.
FA patients were the shortest of the 3 groups and had the
lowest BMI Z-score, but their percent fat and lean body mass
were similar to the other groups after adjusting for height
and Tanner stage. Consistent with previous reports, hypo-
thyroidism was common among FA patients (30% in FA
versus 0% in healthy controls), although it was not as com-
mon as in cancer patients (54%). All patients with hypothy-
roidism were euthyroid (normal free T4 and TSH) on thyroid
hormone replacement at the time of evaluation. A signiﬁcant
proportion of those FA patients whowere in the pubertal age
had hypergonadotropic hypogonadism (20% in FA versus 0%
in healthy controls). The mean levels of sex hormones
(estradiol and testosterone), however, did not differ between
the groups.
BMD in FA Children versus Healthy Controls
As shown in Table 2, FA patients had signiﬁcantly lower
TBMD Z-scores and LBMD Z-scores compared with healthy
controls, and a higher proportion of FA patients had TBMD
and LBMD Z-scores  1 compared with healthy controls.
However, after adjusting for HAZ, only the differences in
TBMD Z-scores remained signiﬁcant. FA patients had mean
TBMDHAZ Z-score .8 compared with .01 in healthy controls.
Also, a higher proportion of FA patients had TBMDHAZ Z-
score1 comparedwith healthy controls (42% versus 11%).
Adjusting for age at study, gender, and Tanner stage did not
change the statistical signiﬁcance of any of these differences
(Figure 1). Six FA patients were on growth hormone treat-
ment at the time of DXA evaluation. Their BMD measure-
ments did not differ signiﬁcantly from those of FA patients
who were not receiving growth hormone (P ¼ .11 for
TBMDHAZ and P ¼ .22 for LBMDHAZ).
BMD in FA HCT Group versus cancer HCT Group
This study’s secondary goal was to determine whether
BMD is affected to a similar degree in children with FA and
Table 1
Characteristics of the Study Groups
Characteristic FA HCT (A) Cancer HCT (B) Healthy Controls (C) Pairwise P Values
A versus C A versus B B versus C
N 20 13 90 - - -
Male 11 (55) 12 (92) 44 (49) .61 .04 .0160
Race*
Non-Black 19 (95) 12 (92) 90 (100) .18 >.99 .13
Black 1 (5) 1 (8) 0 (0)
Age at evaluation, yr 11.9  1.4 12.2  1.0 12.2  1.1 .20 .77 .23
Range 10.1-14.0 11.0-13.6 10.1-13.9
Age at HCT, yr 9.0  2.0 5.7  2.8 NA NA .0013 NA
Range 5.2-12.3 1.2-9.4
Years since HCT 2.8  1.6 6.5  3.0 NA NA .0010 NA
Range 1.0-6.1 2.7-11.3
Type of transplantation*
Autologous 0 (0) 1 (8) NA NA .39 NA
Allogeneic 20 (100) 12 (92)
Conditioning regimen* 0 (0) 0 (0)
Chemotherapy only NA NA .05 NA
Chemo þ TBI 20 (100) 10 (77)
Chemo þ TBI þ CRT 0 (0) 3 (23)
Acute GVHD 3 (15) 8 (62) NA NA .0092 NA
Chronic GVHD 1 (5) 5 (38) NA NA .0248 NA
Tanner stage* (mean) 2.1 1.9 2.6 .14 .94 .16
I 9 (50) 6 (55) 20 (22)
II-III 5 (28) 4 (36) 46 (52)
IV-V 4 (22) 1 (9) 23 (26)
Missing 2 2 1
Height Z-score 2.3  1.4 .6  .4 .4  1.0 <.0001 <.0001 <.0001
BMI Z-score 1.2  2.0 .3  1.0 .5  1.0 .0006 .002 .93
Percent fat mass 26.4  14.2 28.4  9.6 25.5  9.9 .74 .49 .14
Lean body mass
Unadjusted 20.5  5.4 28.0  3.9 34.3  7.2 <.0001 <.0001 .98
Adjustedy 30.6  1.4 30.9  .5 31.9  .4 .40 .80 .003
Hypothyroidism 6 (30) 7 (54) 0 <.0001 .28 <.0001
Hypogonadismz 3 (20) 1 (8) 0 .003 .61 .13
Testosterone (ng/dL) 116 118 143 .59 .92 .54
Estradiol (pg/mL) 53 NA 37 .54 NA NA
NA indicates not applicable; CRT, cranial radiation therapy.
Data are presented as average  SD, adjusted average  SE for adjusted characteristics, or n (%).
To account for multiple comparisons, P value < .0167 is considered statistically signiﬁcant using a Bonferroni adjustment (marked in bold).
* P value refers to the difference, between groups, among the available categories.
y Expressed in kg, adjusted for height (cm) and Tanner stage.
z Hypergonadotropic hypogonadism for females >10 year and males >11 years.
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shown in Table 2. FA HCT and cancer HCT groups did not
differ signiﬁcantly in HAZ-adjusted TBMD Z-scores, LBMD
Z-scores, or the percentage of patients with HAZ-adjustedTable 2
DXA Measures of Bone Mineral Density
Characteristic FA HCT (A) Cancer HCT (B)
n 20 13
TBMD Z-score
TBMDage Z-score (mean  SD) 1.3 (1.0) .2 (.7)
TBMDHAZ Z-score (mean  SD) .8 (.9) .5 (.8)
TBMDage Z-score  1, n (%)* 13 (65) 2 (15)
TBMDHAZ Z-score  1, n (%)y 8 (42) 4 (31)
LBMD Z-score
LBMDage Z-score (mean  SD) .9 (1.1) .2 (.9)
LBMDHAZ Z-score (mean  SD)z .08 (.9) .04 (.9)
LBMDage Z-score  1, n (%)x 10 (50) 3 (23)
LBMDHAZ Z-score  1, n (%) 1 (5) 2 (15)
BMDage Z-score is based on chronological age and sex; BMDHAZ Z-score indicates ad
[15].
To account for multiple comparisons, P value < .0167 is considered statistically sig
* TBMD data were missing for 2 controls.
y Height or TBMD data were missing for 2 controls and 1 FA patient.
z LBMD data were missing for 1 control.
x Height or LBMD data were missing for 1 control and 1 FA patient.Z-scores  1. Cancer patients had intermediate values
between the other 2 groups in terms of both TBMDHAZ Z-
score (.8 in FA HCT versus .5 in cancer HCT versus .01 in
healthy controls), and prevalence of TBMDHAZ Z-score  1Healthy Controls (C) Pairwise P Values
A versus C A versus B B versus C
90 - - -
.7 (1.0) <.0001 <.0001 .006
.01 (.9) .0004 .16 .11
3 (3) <.0001 .0096 .09
10 (11) .0032 .24 .02
.2 (1.0) .0003 .04 .62
.02 (1.0) .77 .91 .94
9 (10) <.0001 .62 .0032
11 (12) .45 .23 .51
justment for height-for-age Z-score (HAZ) using the approach of Zemel et al.
niﬁcant using a Bonferroni adjustment (marked in bold).
Figure 1. Total body BMD Z-score adjusted for height-for-age Z-score, age at
study, gender, and Tanner stage. Average adjusted TBMDHAZ Z-score did not
differ signiﬁcantly between children with FA versus cancer after trans-
plantation. Cancer HCT group showed an intermediate adjusted average
TBMDHAZ Z-score, between healthy controls and FA HCT group. Data are shown
as adjusted average  SE. P value is calculated from the analysis with
adjustment of age at study, gender, and Tanner stage.
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controls). Adjusting for age at study, gender, and Tanner
stage did not change the statistical signiﬁcance of these
ﬁndings (Figure 1). The adjusted average TBMDHAZ Z-score
was .7 in FA HCT (P ¼ .0001 compared with healthy con-
trols) versus .4 in cancer HCT (P ¼ .15 compared with
healthy controls) versus .01 in healthy controls. Because FA
patients and cancer patients differed in age at HCT and time
since HCT, BMD analyses were additionally adjusted for these
variables. Again, no signiﬁcant differences between these 2
groups were found in TBMDHAZ or LBMDHAZ Z-scores.
Analysis of Risk Factors Associated with Lower BMD in
FA Patients
The following risk factors were evaluated to determine
association with lower TBMDHAZ or LBMDHAZ Z-score in FA
patients: age at HCT, sex, BMI Z-score, percent fat mass, lean
body mass adjusted for height, vitamin D deﬁciency (deﬁned
as a 25-hydroxyvitamin D level < 30 mg/L), hypothyroidism,
and hypergonadotropic hypogonadism. In FA patients, only
lower BMI Z-score and lower percent fat mass were associ-
ated with lower TBMDHAZ Z-scores and lower LBMDHAZ Z-
scores (Table 3). For example, 1 Z-score decrease in BMI was
associated with .2 decrease in TBMDHAZ Z-score and .3
decrease in LBMDHAZ Z-score. For percent fat mass, a 1%
decrease was associated with .04 decrease in TBMDHAZ Z-
score and .04 decrease in LBMDHAZ Z-score.
DISCUSSION
This study identiﬁed bone mineral deﬁcits among FA
patients previously treated with HCT. These deﬁcits,Table 3
Factors Signiﬁcantly associated with Lower BMDHAZ Z-scores in FA Patients
Risk Factor Comparison Estimated
Change (SE)
P Value
TBMDHAZ Z-score
BMI Z-score 1 Z-score unit decrease .2 (.094) .0196
Percent fat mass 1% decrease .04 (.013) .0068
LBMDHAZ Z-score
BMI Z-score 1 Z-score unit decrease .3 (.082) .0027
Percent fat mass 1% decrease .04 (.012) .0005
This table includes only risk factors with P < .05. Other risk factors included
age at HCT, sex, lean body mass adjusted for height, vitamin D deﬁciency
(deﬁned as vitamin D level <30 mg/L), hypothyroidism, and hyper-
gonadotropic hypogonadism.averaging about .8 SD after adjusting for short stature, were
observed speciﬁcally in TBMD but not LBMD. Different
skeletal regions differ signiﬁcantly in bone composition.
Eighty percent of the whole skeleton is cortical bone,
whereas the lumbar spine consists largely of trabecular
(cancellous) bone (66%) [17]. Our study and others suggest
predominant involvement of cortical bone in HCT recipients
[6,18]. Trabecular bone is more metabolically active than
cortical bone and is likely to respond faster to factors that
affect bone metabolism. In this study, FA patients were
evaluated a median of 2.2 years (range, 1 to 6) after HCT, so
early changes in bone remodeling could have been missed.
Although differences in bone composition (ie, cortical versus
trabecular) may account for some of the observed differences
in BMD measures depending on the skeletal site, a more
direct measure is needed to distinguish cortical and trabec-
ular bone, such as peripheral quantitative computed to-
mography. Using peripheral quantitative computed
tomography, deﬁcits in both cortical and trabecular bone
were observed in children and young adults, mostly with
leukemia, a median of 7 years after HCT [7]. Future studies
are needed to address regional bone remodeling in FA pa-
tients before and after HCT.
In children as well as adults, DXA remains the most
widely used modality for evaluating BMD due to its low ra-
diation exposure, ease of use, and availability of robust
reference data. It is recognized, however, that DXA tends to
underestimate BMD in children with short stature. This is
particularly relevant to children with FA, whose average
height is < 2 SD [3]. Hence, methods have been developed
to adjust for short stature [15,19]. In this study, although
adjustment for height increased BMD Z-scores in FA patients,
their TBMD deﬁcit remained substantial. The mean height-
adjusted TBMD Z-score was 0.8 in FA patients compared
with a mean of 0.01 in a normal population. A difference of .8
SD is likely to be clinically signiﬁcant because fracture risk
increases gradually along a gradient, not abruptly at a
threshold. Although the incidence of fractures in the FA
population is not known, in a general pediatric population
the risk of fracture increases by an estimated 37% for a 0.5 Z-
score reduction, based on logistic regression results in a
study by Clark et al. [20]. Moreover, 42% of FA patients had
height-adjusted TBMD Z-scores  1, which is remarkable
given that these deﬁcits are already present at a young age, at
the time when reaching an optimal peak BMD is critical for
long-term bone health.
The only other study reported in the literature that
focused on BMD exclusively in FA patients was a cross-
sectional analysis of LBMD (but not TBMD) in 37 FA pa-
tients (ages 4 to 23 years, 19 without HCT and 18 after HCT)
[12]. Although about 50% of these FA children had LBMD Z-
scores for chronological age below 1 SD, most patients had
normal BMD when adjusted for height. Height-adjusted
LBMD Z-scores for both FA patients who underwent trans-
plantation and FA patients who didn’t undergo trans-
plantation were within normal limits (average Z-scores of .4
and .8, respectively), leading to the conclusion that BMD is
normal in children with FA. It was noted, however, that after
adjusting for height, a higher proportion of FA patients who
had previously undergone HCT had BMD < 1 SD compared
with those without history of HCT (28% versus 0%). Our study
corroborates that LBMD does not appear to be affected in FA
children, but it also highlights the importance of measuring
TBMD, which did show a deﬁcit compared with healthy
controls.
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We have previously shown that bone loss after pediatric HCT
is due to a decrease in bone formation [9] and an increase in
bone resorption [21]. FA patients were included in both
studies. Both hypogonadism and vitamin D deﬁciency may
contribute to the imbalance between bone formation and
resorption. Although hypergonadotropic hypogonadism was
prevalent among FA patients, it was not associated with
lower HAZ-adjusted BMDHAZ, perhaps because the mean
levels of sex hormones did not differ between the groups,
suggesting only partial hypogonadism. One half of the FA
patients had a 25-hydroxyvitamin D level <30 mg/L, even
though one third of patients were already on vitamin D
replacement at the time of evaluation. The recommended
use of sunscreen to reduce the risk of skin cancer or exac-
erbation of cutaneous GVHD may contribute to a high
prevalence of vitamin D deﬁciency in FA patients. Never-
theless, vitamin D deﬁciency was not associated with lower
BMDHAZ in these patients. Exposure to TBI is also a risk factor
for bone loss after HCT, presumably due to damaging effects
of radiation on osteoblasts and the stromal microenviron-
ment [7]. Although FA patients receive a lower dose of TBI
and reduced chemotherapy doses relative to non-FA patients
undergoing HCT, biologically the effect is the same and fully
myeloablative, as FA patients have impaired DNA repair
mechanisms. In this study, FA HCT patients were as severely
if not more severely affected in terms of BMD outcome than
cancer HCT patients, who received signiﬁcant amounts of
chemotherapy for months or years before HCT.
Impaired bone metabolism may also be intrinsic to FA.
The “intrinsic” hypothesis is supported by the observation
that reduced BMD occurs in adults with FA without previous
exposure to HCT [11] and by the presence of skeletal
anomalies, including radial-ray defects (thumb and radius
abnormalities), brachydactyly, vertebral anomalies, and
others [2], which indicate abnormal bone morphogenesis. A
genetic component is likely to play an important role in FA
patients as it is estimated that, in general, 60% to 80% of the
variability in bone mass between individuals is determined
by genetic factors [22]. Morphogenetic events during limb
development are regulated by several developmental path-
ways, including ﬁbroblast growth factor, sonic hedgehog,
retinoid signaling, and wingless-type MMTV integration site
family (Wnt) pathway [23,24]. Among these, Wnt signaling
emerges as an attractive candidate because it regulates not
only skeletal embryonic development but also postnatal
bone homeostasis and hematopoiesis [25]. Wnt signaling
regulates the function, differentiation, and survival of oste-
oblasts, osteoclasts, and chondrocytes within the growth
plate. Defects in Wnt signaling lead to truncated limbs,
chondrocyte differentiation defects, short stature, and oste-
oporosis [25-27]. One of the key mediators of Wnt signaling
is b-catenin [27]. A recent study has shown that 1 of the
proteins encoded by the FA-associated gene FANCL is directly
involved in regulating post-translational modiﬁcation of b-
catenin, enhancing its nuclear function [28]. FANCL-deﬁcient
progenitor cells exhibit reduced transcription of Wnt-
responsive genes, resulting in impaired hematopoiesis. The
interaction between FANCL and b-catenin may be facilitated
by FANCA and FANCG [28]. It remains to be determined
whether dysregulation of the Wnt/b-catenin or other
developmental pathways can provide a unifying mechanism
for a constellation of ﬁndings in FA patients, including short
stature, limb and vertebral deformities, and abnormal bone
homeostasis.This study has some limitations. First, BMD evaluation
was not performed before HCT, thus, not allowing a separate
estimate of HCT’s effect. Second, the population was pre-
dominantly white, limiting the ability to generalize ﬁndings
to other racial groups. Third, inclusion of the head in TBMD
measures may have underestimated BMD deﬁcits in FA pa-
tients. Fourth, data on fractures were not collected. Never-
theless, the inclusion of a large healthy control group
strengthened the validity of the main observation that FA
patients have reduced TBMD.
In summary, this study describes BMD deﬁcits in post-
HCT FA pediatric population. The study shows that (1)
TBMD, but not LBMD, is reduced in FA patients compared
with healthy controls even after adjusting for shortness, (2)
FA HCT population and cancer HCT population do not differ
signiﬁcantly in height-adjusted TBMD Z-scores or LBMD Z-
scores, and (3) BMD deﬁcit in FA after HCT cannot be
explained by hypogonadism or vitamin D deﬁciency. The
association between lower BMI and lower BMD underscores
the importance of optimizing nutritional status in these pa-
tients. The current recommendation for children undergoing
HCT is to perform a DXA scan before HCT, 1 year after HCT,
and annually thereafter if BMD Z-score is < 1 [29]. This
recommendation is also applicable to patients with FA.
Following this regimented approach will allow better
determination of the degree to which BMD deﬁcits are
intrinsic to FA patients and the inﬂuence of HCT on BMD.
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